Strategies to Target Glucose Metabolism in Tumor Microenvironment on Cancer by Flavonoids

References

• Cantor JR and Sabatini DM: Cancer cell metabolism: One hallmark, many faces. Cancer Discov 2, 881–898, 2012.
   PubMed Web of Science ®Google Scholar
• Sato A, Sunayama J, Okada M, Watanabe E, Seino S, et al.: Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK. Stem Cells Transl Med 1, 811–824, 2012.
   PubMed Web of Science ®Google Scholar
• Tennant DA, Durán RV, Boulahbel H, and Gottlieb E: Metabolic transformation in cancer. Carcinogenesis 30, 1269–1280, 2009.
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, and Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033, 2009.
   PubMed Web of Science ®Google Scholar
• Martinez-Outschoorn U, Sotgia F, and Lisanti MP: Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function. Semin Oncol 41, 195–216, 2014.
   PubMed Web of Science ®Google Scholar
• Carmona-Fontaine C, Bucci V, Akkari L, Deforet M, Joyce JA, et al.: Emergence of spatial structure in the tumor microenvironment due to the Warburg effect. Proc Natl Acad Sci USA 110, 19402–19407, 2013.
   PubMed Web of Science ®Google Scholar
• El Sayed SM, El-Magd RM, Shishido Y, Chung SP, Diem TH, et al.: 3-Bromopyruvate antagonizes effects of lactate and pyruvate, synergizes with citrate and exerts novel anti- glioma effects. J Bioenerg Biomembr 44, 61–79, 2012.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Jiang W, McGinley JN, and Thompson HJ: 2-Deoxyglucose as an energy restriction mimetic agent: effects on mammary carcinogenesis and on mammary tumor cell growth in vitro. Cancer Res 65, 7023–7030, 2005.
   PubMed Web of Science ®Google Scholar
• Pelicano H, Martin DS, Xu RH, and Huang P: Glycolysis inhibition for anticancer treatment. Oncogene 25, 4633–4646, 2006.
   PubMed Web of Science ®Google Scholar
• Pedersen PL: The cancer cell's “power plants” as promising therapeutic targets: an overview. J Bioenerg Biomembr 39, 1–12, 2007.
   PubMed Web of Science ®Google Scholar
• Martin KR: Targeting apoptosis with dietary bioactive agents. Exp Biol Med (Maywood) 231, 117–129, 2006.
   PubMed Web of Science ®Google Scholar
• de Boer VC, van Schothorst EM, Dihal AA, van der Woude H, Arts IC, et al.: Chronic quercetin exposure affects fatty acid catabolism in rat lung. Cell Mol Life Sci 63, 2847–2858, 2006.
   PubMed Web of Science ®Google Scholar
• Dihal AA, de Boer VC, van der Woude H, Tilburgs C, Bruijntjes JP, et al.: Quercetin, but not its glycosidated conjugate rutin, inhibits azoxymethane-induced colorectal carcinogenesis in F344 rats. J Nutr 136, 2862–2867, 2006.
   PubMed Web of Science ®Google Scholar
• Dihal AA, van der Woude H, Hendriksen PJ, Charif H, Dekker LJ, et al.: Transcriptome and proteome profiling of colon mucosa from quercetin fed F344 rats point to tumor preventive mechanisms, increased mitochondrial fatty acid degradation and decreased glycolysis. Proteomics 8, 45–61, 2008.
   PubMed Web of Science ®Google Scholar
• Dang CV: Links between metabolism and cancer. Genes Dev 26, 877–890, 2012.
   PubMed Web of Science ®Google Scholar
• Garber K: Energy boost: the Warburg effect returns in a new theory of cancer. J Natl Cancer Inst 96, 1805–1806, 2004.
   PubMedGoogle Scholar
• Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, et al.: Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162, 1229–1241, 2015.
   PubMed Web of Science ®Google Scholar
• Hsu PP and Sabatini DM: Cancer cell metabolism: Warburg and beyond. Cell 134, 703–707, 2008.
   PubMed Web of Science ®Google Scholar
• Ralph SJ, Rodríguez-Enríquez S, Neuzil J, and Moreno-Sánchez R: Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger. Mol Aspects Med 31, 29–59, 2013.
   Web of Science ®Google Scholar
• Bourdon A, Minai L, Serre V, Jais JP, Sarzi E, et al.: Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat Genet 39, 776–780, 2007.
   PubMed Web of Science ®Google Scholar
• Burns DM and Richter JD: CPEB regulation of human cellular senescence, energy metabolism, and p53 mRNA translation. Genes Dev 22, 3449–3460, 2008.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, et al.: Role of HIF–1αlpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394485–394490, 1998.
   Web of Science ®Google Scholar
• Hanahan D and Weinberg Robert A: Hallmarks of cancer: The next generation. Cell 144, 646–674, 2011.
   PubMed Web of Science ®Google Scholar
• Contractor T and Harris CR: p53 negatively regulates transcription of the pyruvate dehydrogenase kinase Pdk2. Cancer Res 72, 560–567, 2012.
   PubMed Web of Science ®Google Scholar
• Sutendra G, Dromparis P, Kinnaird A, Stenson TH, Haromy A, et al.: Mitochondrial activation by inhibition of PDKII suppresses HIF–1α signaling and angiogenesis in cancer. Oncogene 32, 1638–1650, 2013.
   PubMed Web of Science ®Google Scholar
• Kim JW and Dang CV: Multifaceted roles of glycolytic enzymes. Trends Biochem Sci 30, 142–150, 2005.
   PubMed Web of Science ®Google Scholar
• Kim JW, Tchernyshyov I, Semenza GL, and Dang V: HIF–1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3, 177–185, 2012.
   Web of Science ®Google Scholar
• Kluza J, Corazao-Rozas P, Touil Y, Jendoubi M, Maire C, et al.: Inactivation of the HIF–1α/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants. Cancer Res 72, 5035–5047, 2012.
   PubMed Web of Science ®Google Scholar
• Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, et al.: Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 208, 313–326, 2011.
   PubMed Web of Science ®Google Scholar
• Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, et al.: Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2, 1ra34, 2010.
   Web of Science ®Google Scholar
• Semenza GL: Hypoxia-inducible factors in physiology and medicine. Cell 148, 399–408, 2012.
   PubMed Web of Science ®Google Scholar
• Wojtaszewski JFP, Hansen BF, Urso B, and Richter EA: Wortmannin inhibits both insulin- and contraction-stimulated glucose uptake and transport in rat skeletal muscle. J Appl Physiol 81, 1501–1509, 1996.
   PubMed Web of Science ®Google Scholar
• Purcell SH, Chi MM, and Moley KH: Insulin-stimulated glucose uptake occurs in specialized cells within the cumulus oocyte complex. Endocrinology 153, 2444–2454, 2012.
   PubMed Web of Science ®Google Scholar
• Zhou SH, Fan J, Chen XM, Cheng KJ, and Wang SQ: Inhibition of cell proliferation and glucose uptake in human laryngeal carcinoma cells by antisense oligonucleotides against glucose transporter–1. Head Neck-J Sci Spec 31, 1624–1633, 2009.
   PubMed Web of Science ®Google Scholar
• Beltrán FA, Acuña AI, Miró MP, Angulo C, Concha II, et al.: Ascorbic acid-dependent GLUT3 inhibition is a critical step for switching neuronal metabolism. J Cell Physiol 226, 3286–3294, 2011.
   PubMed Web of Science ®Google Scholar
• Liu Y, Li YM, Tian RF, Liu WP, Fei Z, et al.: The expression and significance of HIF–1αlpha and GLUT–3 in glioma. Brain Res 1304, 149–154, 2009.
   PubMed Web of Science ®Google Scholar
• Nalini N, Aranganathan S, and Kabalimurthy J: Chemopreventive efficacy of hesperetin (citrus flavonone) against 1, 2-dimethylhydrazine-induced rat colon carcinogenesis. Toxicol Mech Method 22, 397–408, 2012.
   PubMed Web of Science ®Google Scholar
• Patil JR, Chidambara Murthy KN, Jayaprakasha GK, Chetti MB, et al.: Bioactive compounds from Mexican lime (Citrus aurantifolia) juice induce apoptosis in human pancreatic cells. J Agric Food Chem 57, 10933–10942, 2009.
   PubMed Web of Science ®Google Scholar
• Sivagami G, Vinothkumar R, Preethy CP, Preethy CP, Riyasdeen A, et al.: Role of hesperetin (a natural flavonoid) and its analogue on apoptosis in HT–29 human colon adenocarcinoma cell line–a comparative study. Food Chem Toxicol 50, 660–671, 2012.
   PubMed Web of Science ®Google Scholar
• Pedersen PL: Warburg, me and Hexokinase 2: multiple discoveries of key molecular events underlying one of cancer's most common phenotypes, the “Warburg Effect”, i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 39, 211–222, 2007.
   PubMed Web of Science ®Google Scholar
• Brand W, Oosterhuis B, Krajcsi P, Barron D, Dionisi F, et al.: Interaction of hesperetin glucuronide conjugates with human BCRP, MRP2 and MRP3 as detected in membrane vesicles of overexpressing baculo virus infected Sf9 cells. Biopharm Drug Dispos 32, 530–535, 2011.
   PubMed Web of Science ®Google Scholar
• Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, et al.: Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64, 3892–3899, 2004.
   PubMed Web of Science ®Google Scholar
• Kim JW, Tchernyshyov I, Semenza GL, and Dang CV: HIF–1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3, 177–185, 2006.
   PubMed Web of Science ®Google Scholar
• Papandreou I, Cairns RA, Fontana L, Lim AL, and Denko NC: HIF–1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3, 187–197, 2006.
   PubMed Web of Science ®Google Scholar
• Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, et al.: c-Myc suppression of miR–23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458(7239), 762–765, 2009.
   PubMed Web of Science ®Google Scholar
• Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, et al.: Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA 107(5), 2037–2042, 2010.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Liu H, Liu Z, Ding Y, Ledoux SP, et al.: Overcoming trastuzumabb-resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res 71, 4585–4597, 2011.
   PubMed Web of Science ®Google Scholar
• Zhou M, Zhao Y, Ding Y, Liu H, Liu Z, et al.: Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer 9, 33, 2010.
   PubMed Web of Science ®Google Scholar
• Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, et al.: Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18, 207–219, 2010.
   PubMed Web of Science ®Google Scholar
• Lisanti MP, Martinez-Outschoorn UE, and Sotgia F: Oncogenes induce the cancer-associated fibroblast phenotype: metabolic symbiosis and ‘‘fibroblast addiction’’ are new therapeutic targets for drug discovery. Cell Cycle 12, 2723–2732, 2013.
   PubMed Web of Science ®Google Scholar
• Yoo BC, Ku JL, Hong SH, Shin YK, Park SY, et al.: Decreased pyruvate kinase M2 activity linked to cisplatin resistance in human gastric carcinoma cell lines. Int J Cancer 108, 532–539, 2004.
   PubMed Web of Science ®Google Scholar
• Martinez-Balibrea E, Plasencia C, Ginés A, Martinez-Cardús A, Musulén E, et al.: A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines. Mol Cancer Ther 8(4), 771–778, 2009.
   PubMed Web of Science ®Google Scholar
• Li SL, Ye F, Cai WJ, Hu HD, Hu P, et al.: Quantitative proteome analysis of multidrug resistance in human ovarian cancer cell line. J Cell Biochem 109(4), 625–633, 2010.
   PubMed Web of Science ®Google Scholar
• Lin Y, Lv F, Liu F, Guo X, Fan Y, et al.: High expression of pyruvate kinase m2 is associated with chemosensitivity to epirubicin and 5-fluorouracil in breast cancer. J Cancer 6(11), 1130–1139, 2015.
   PubMed Web of Science ®Google Scholar
• Fukuda S, Miyata H, Miyazaki Y, Makino T, Takahashi T, et al.: Pyruvate kinase M2 modulates esophageal squamous cell carcinoma chemotherapy response by regulating the pentose phosphate pathway. Ann Surg Oncol 22(Suppl 3), S1461–S1468, 2015.
   PubMed Web of Science ®Google Scholar
• Guo W, Zhang Y, Chen T, Wang Y, Xue J, et al.: Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model. J Cancer Res Clin Oncol 137(1), 65–72, 2011.
   PubMed Web of Science ®Google Scholar
• Shi HS, Li D, Zhang J, Wang YS, Yang L, et al.: Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice. Cancer Sci 101(6), 1447–1453, 2010.
   PubMed Web of Science ®Google Scholar
• Sun Q, Chen X, Ma J, Peng H, Wang F, et al.: Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA 108(10), 4129–4134, 2011.
   PubMed Web of Science ®Google Scholar
• Leisching GR, Loos B, Botha MH, and Engelbrecht AM: The role of mTOR during cisplatin treatment in an in vitro and ex vivo model of cervical cancer. Toxicology 335, 72–78, 2015.
   PubMed Web of Science ®Google Scholar
• Faried LS, Faried A, Kanuma T, Aoki H, Sano T, et al.: Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy. Mol Carcinog 47(6), 446–457, 2008.
   PubMed Web of Science ®Google Scholar
• Damia G and Garattini S: The pharmacological point of view of resistance to therapy in tumors. Cancer Treat Rev 40, 909–916, 2014.
   PubMed Web of Science ®Google Scholar
• Sullivan EJ, Kurtoglu M, Brenneman R, Liu H, and Lampidis TJ: Targeting cisplatin-resistant human tumor cells with metabolic inhibitors. Cancer Chemother Pharmacol 73, 417–427, 2014.
   PubMed Web of Science ®Google Scholar
• Le Calve B, Rynkowski M, Le Mercier M, Bruyere C, Lonez C, et al.: Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Neoplasia (New York) 12, 727–739, 2010.
   PubMed Web of Science ®Google Scholar
• Morfouace M, Lalier L, Bahut M, Bonnamain V, Naveilhan P, et al.: Comparison of spheroids formed by rat glioma stem cells and neural stem cells reveals differences in glucose metabolism and promising therapeutic applications. J Biol Chem 287(40), 33664–33674, 2010.
   Web of Science ®Google Scholar
• Backos DS, Fritz KS, McArthur DG, Kepa JK, Donson AM, et al.: Glycation of glutamate cysteine ligase by 2-deoxy-d-ribose and its potential impact on chemoresistance in glioblastoma. Neurochem Res 38(9), 1838–1849, 2013.
   PubMed Web of Science ®Google Scholar
• Zhang JZ, Behrooz A, and Ismail-Beigi F: Regulation of glucose transport by hypoxia. Am J Kidney Dis 34, 189–202, 1999.
   PubMed Web of Science ®Google Scholar
• Airley RE and Mobasheri A: Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 53, 233–256, 2007.
   PubMed Web of Science ®Google Scholar
• Mathieu V, De Nève N, Le Mercier M, Dewelle J, Gaussin JF, et al.: Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastom orthotopic xenograft model. Neoplasia 10, 1383–1392, 2008.
   PubMed Web of Science ®Google Scholar
• Gatenby RA and Gillies RJ: Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4, 891–899, 2004.
   PubMed Web of Science ®Google Scholar
• Boado RJ, Back KL, and Pardridge WM: Gene expression of GLUT–3 and GLUT–1 glucose transporters in human brain tumors. Brain Res Mol Brain Res 27, 51–57, 1994.
   PubMedGoogle Scholar
• Nagamatsu S, Sawa H, Wakizaka A, and Hoshino T: Expression of facilitative glucose transporter isoforms in human brain tumors. J Neurochem. 61, 2048–2053, 1993.
   PubMed Web of Science ®Google Scholar
• James AD, Patel W, Butt Z, Adiamah M, Dakhel R, et al.: The plasma membrane calcium pump in pancreatic cancer cells exhibiting the warburg effect relies on glycolytic ATP. J Biol Chem 290(41), 24760–24771, 2015.
   PubMed Web of Science ®Google Scholar
• Wei L, Dai Q, Zhou Y, Zou M, Li Z, et al.: Oroxylin A sensitizes non-small cell lung cancer cells to anoikis via glucose-deprivation-like mechanisms: c-Src and hexokinase II. Biochim Biophys Acta 1830(6), 3835–3845, 2013.
   PubMed Web of Science ®Google Scholar
• Wei L, Zhou Y, Dai Q, Qiao C, Zhao L, et al.: Oroxylin A induces dissociation of hexokinase II from the mitochondria and inhibits glycolysis by SIRT3- mediated deacetylation of cyclophilin D in breast carcinoma. Cell Death Dis 4, e601, 2013.
   PubMed Web of Science ®Google Scholar
• Liu W, Mu R, Nie FF, Yang Y, Wang J, et al.: MAC-related mitochondrial pathway in oroxylin A -induced apoptosis in human hepatocellular carcinoma HepG2 cells. Cancer Lett 284, 198–207, 2009.
   PubMed Web of Science ®Google Scholar
• Lu Z, Lu N, Li C, Li F, Zhao K, et al.: Oroxylin A inhibits matrix metalloproteinase–2/9 expression and activation by up-regulating tissue inhibitor of metalloproteinase–2 and suppressing the ERK1/2 signaling pathway. Toxicol Lett 209, 211–220, 2012.
   PubMed Web of Science ®Google Scholar
• Yang Y, Hu Y, Gu HY, Lu N, Liu W, et al.: Oroxylin A induces G2/M phase cell-cycle arrest via inhibiting Cdk7-mediated expression of Cdc2/p34 in human gastric carcinoma BGC–823 cells. J Pharm Pharmacol 60, 1459–1463, 2008.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhao L, Zhu LT, Wang Y, Pan D, et al.: Wogonin reverses hypoxia resistance of human colon cancer HCT116 cells via downregulation of HIF–1α and glycolysis, by inhibiting PI3K/Akt signaling pathway. Mol Carcinog 53, E107–E118, 2014.
   PubMed Web of Science ®Google Scholar
• Dihal AA, van der Woude H, Hendriksen PJ, Charif H, Dekker LJ, et al.: Transcriptome and proteome profiling of colon mucosa from quercetin fed F344 rats point to tumor preventive mechanisms, increased mitochondrial fatty acid degradation and decreased glycolysis. Proteomics 8(1), 45–61, 2008.
   PubMed Web of Science ®Google Scholar
• Belt JA, Thomas JA, Buchsbaum RN, and Racker E: Inhibition of lactate transport and glycolysis in Ehrlich ascites tumor cells by bioflavonoids. Biochemistry 18(16), 3506–3511, 1979.
   PubMed Web of Science ®Google Scholar
• Suolinna EM, Lang DR, and Racker E: Quercetin, an artificial regulator of the high aerobic glycolysis of tumor cells. J Natl Cancer Inst 53(5), 1515–1519, 1974.
   PubMedGoogle Scholar
• de Boer VC, de Goffau MC, Arts IC, Hollman PC, and Keijer J: SIRT1 stimulation by polyphenols is affected by their stability and metabolism. Mech Ageing Dev 127(7), 618–627, 2006.
   PubMed Web of Science ®Google Scholar
• Chen V, Staub RE, Baggett S, Chimmani R, Tagliaferri M, et al.: Identification and analysis of the active phytochemicals from the anti-cancer botanical extract Bezielle. PLoS One 7(1), e30107, 2012.
   PubMed Web of Science ®Google Scholar
• Chen F, Zhuang M, Zhong C, Peng J, Wang X, et al.: Baicalein reverses hypoxia-induced 5-FU resistance in gastric cancer AGS cells through suppression of glycolysis and the PTEN/ Akt/HIF–1α signaling pathway. Oncol Rep 33(1), 457–463, 2015.
   PubMed Web of Science ®Google Scholar
• Du GJ, Song ZH, Lin HH, Han XF, Zhang S, et al.: Luteolin as a glycolysis inhibitor offers superior efficacy and lesser toxicity of doxorubicin in breast cancer cells. Biochem Biophys Res Commun 372(3), 497–502, 2008.
   PubMed Web of Science ®Google Scholar
• Melstrom LG, Salabat MR, Ding XZ, Strouch MJ, Grippo PJ, et al.: Apigenin down-regulates the hypoxia response genes: HIF–1α, GLUT–1, and VEGF in human pancreatic cancer cells. J Surg Res 167(2), 173–181, 2011.
   PubMed Web of Science ®Google Scholar
• Macheda ML, Rogers S, and Best JD: Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 202, 654–662, 2005.
   PubMed Web of Science ®Google Scholar
• Cao X, Fang L, Gibbs S, Huang Y, Dai Z, et al.: Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemotherapy Pharmacol 59, 495–505, 2007.
   PubMed Web of Science ®Google Scholar
• McBrayer SK, Cheng JC, Singhal S, Krett NL, Rosen ST, et al.: Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter- directed therapy. Blood 119, 4686–4697, 2012.
   PubMed Web of Science ®Google Scholar
• Araújo JR, Gonçalves P, and Martel F: Chemopreventive effect of dietary polyphenols in colorectal cancer cell lines. Nutr Res 31(2), 77–87, 2011.
   PubMed Web of Science ®Google Scholar
• Hezel AF and Bardeesy N: LKB1; linking cell structure and tumor suppression. Oncogene 27(55), 6908–6919, 2008.
   PubMed Web of Science ®Google Scholar
• Lee LT, Huang YT, Hwang JJ, Lee PP, Ke FC, et al.: Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells. Anticancer Res 22, 1615–1627, 2002.
   PubMed Web of Science ®Google Scholar
• Putter J: Peroxidases. In: Methods of Enzymatic Analysis: II, Bergmeyer HU (ed.).. New York: Academic Press. 1974, 685–690.
   Google Scholar
• Ngala R and Fianko K: Dyslipidaemia and dysglycaemia in HIV-infected patients on highly active anti-retroviral therapy in Kumasi Metropolis. Afr Health Sci 13(4), 1107–1116, 2013.
   PubMedGoogle Scholar
• Moreira L, Araújo I, Costa T, Correia-Branco A, Faria A, et al.: Quercetin and epigallocatechin gallate inhibit glucose uptake and metabolism by breast cancer cells by an estrogen receptor- independent mechanism. Exp Cell Res 319(12), 1784–1795, 2013.
   PubMed Web of Science ®Google Scholar
• Pérez A, Ojeda P, Ojeda L, Salas M, Rivas CI, et al.: Hexose transporter GLUT1 harbors several distinct regulatory binding sites for flavones and tyrphostins. Biochemistry 50(41), 8834–8845, 2011.
   PubMed Web of Science ®Google Scholar
• Kwon O, Eck P, Chen S, Corpe CP, Lee JH, et al.: Inhibition of the intestinal glucose transporter GLUT2 by flavonoids. FASEB J 21, 366–377, 2007.
   PubMed Web of Science ®Google Scholar
• Minutolo F, Macchia M, Katzenellenbogen BS, and Katzenellenbogen JA: Estrogen receptor β ligands: recent advances and biomedical applications. Med Res Rev 31, 364–442, 2011.
   PubMed Web of Science ®Google Scholar
• Harmon AW and Patel YM: Naringenin inhibits glucose uptake in MCF–7 breast cancer cells: a mechanism for impaired cellular proliferation. Breast Cancer Res Treat 85(2), 103–110, 2004.
   PubMed Web of Science ®Google Scholar
• Totta P, Acconcia F, Leone S, Cardillo I, and Marino M: Mechanisms of naringenin-induced apoptotic cascade in cancer cells: involvement of estrogen receptor alpha and beta signaling. IUBMB Life 56(8), 491–499, 2004.
   PubMed Web of Science ®Google Scholar
• Park JB: Flavonoids are potential inhibitors of glucose uptake in U937 cells. Biochem Biophys Res Comm 260, 568–574, 1999.
   PubMed Web of Science ®Google Scholar
• Brown RS, Goodman TM, Zasadny KR, Greenson JK, and Wahl RL: Expression of hexokinase II and Glut–1 in untreated human breast cancer. Nucl Med Biol 29, 443–453, 2002.
   PubMed Web of Science ®Google Scholar
• Wojtaszewski JFP, Hansen BF, Urso B, and Richter EA: Wortmannin inhibits both insulin- and contraction-stimulated glucose uptake and transport in rat skeletal muscle. J Appl Physiol 81, 1501–1509, 1996.
   PubMed Web of Science ®Google Scholar
• Purcell SH, Chi MM, and Moley KH: Insulin-stimulated glucose uptake occurs in specialized cells within the cumulus oocyte complex. Endocrinology 153, 2444–2454, 2012.
   PubMed Web of Science ®Google Scholar
• Zhou SH, Fan J, Chen XM, Cheng KJ, and Wang SQ: Inhibition of cell proliferation and glucose uptake in human laryngeal carcinoma cells by antisense oligonucleotides against glucose transporter–1. Head Neck-J Sci Spec 31, 1624–1633, 2009.
   PubMed Web of Science ®Google Scholar
• Nalini N, Aranganathan S, and Kabalimurthy J: Chemopreventive efficacy of hesperetin (citrus flavonone) against 1, 2-dimethylhydrazine-induced rat colon carcinogenesis. Toxicol Mec Method 22(5), 397–408, 2012.
   PubMed Web of Science ®Google Scholar
• Patil JR, Chidambara Murthy KN, Jayaprakasha GK, Chetti MB, et al.: Bioactive compounds from Mexican lime (Citrus aurantifolia) juice induce apoptosis in human pancreatic cells. J Agric Food Chem 57, 10933–10942, 2009.
   PubMed Web of Science ®Google Scholar
• Sivagami G, Vinothkumar R, Preethy CP, Preethy CP, Riyasdeen A, et al.: Role of hesperetin (a natural flavonoid) and its analogue on apoptosis in HT–29 human colon adenocarcinoma cell line–a comparative study. Food Chem Toxicol 50, 660–671, 2012.
   PubMed Web of Science ®Google Scholar
• Brand W, Oosterhuis B, Krajcsi P, Barron D, Dionisi F, et al.: Interaction of hesperetin glucuronide conjugates with human BCRP, MRP2 and MRP3 as detected in membrane vesicles of overexpressing baculovirusinfected Sf9 cells. Biopharm Drug Dispos 32, 530–535, 2011.
   PubMed Web of Science ®Google Scholar
• Siegelin MD, Gaiser T, Habel A, and Siegelin Y: Myricetin sensitizes malignant glioma cells to TRAIL-mediated apoptosis by down-regulation of the short isoform of FLIP and bcl–2. Cancer Lett 283(2), 230–238, 2009.
   PubMed Web of Science ®Google Scholar
• Seibert H, Maser E, Schweda K, Seibert S, and Gülden M: Cytoprotective activity against peroxide-induced oxidative damage and cytotoxicity of flavonoids in C6 rat glioma cells. Food Chem Toxicol 49(9), 2398–2407, 2011.
   PubMed Web of Science ®Google Scholar
• Panickar KS and Anderson RA: Mechanisms underlying the protective effects of myricetin and quercetin following oxygen-glucose deprivation-induced cell swelling and the reduction in glutamate uptake in glial cells. Neuroscience 183, 1–14, 2011.
   PubMed Web of Science ®Google Scholar
• Meireles M, Martel F, Araújo J, Santos-Buelga C, Gonzalez-Manzano S, et al.: Characterization and modulation of glucose uptake in a human blood-brain barrier model. J Membr Biol 246(9), 669–677, 2013.
   PubMed Web of Science ®Google Scholar
• Sahu SC and Gray GC: Pro-oxidant activity of flavonoids: effects on glutathione and glutathione S-transferase in isolated rat liver nuclei. Cancer Lett 104(2), 193–196, 1996.
   PubMed Web of Science ®Google Scholar
• Zhan T, Digel M, Küch EM, Stremmel W, and Füllekrug J: Silybin and dehydrosilybin decrease glucose uptake by inhibiting GLUT proteins. J Cell Biochem 112(3), 849–859, 2011.
   PubMed Web of Science ®Google Scholar
• González-Menendez P, Hevia D, Rodriguez-Garcia A, Mayo JC, and Sainz RM: Regulation of GLUT transporters by flavonoids in androgen-sensitive and insensitive prostate cancer cells. Endocrinology 155(9), 3238–3250, 2014.
   PubMed Web of Science ®Google Scholar
• Bao YY, Zhou SH, Fan J, and Wang QY: Anticancer mechanism of apigenin and the implications of GLUT–1 expression in head and neck cancers. Future Oncol 9(9), 1353–1364, 2013.
   PubMed Web of Science ®Google Scholar
• Melstrom LG, Salabat MR, Ding XZ, Strouch MJ, Grippo PJ, et al.: Apigenin down-regulates the hypoxia response genes: HIF–1α, GLUT–1, and VEGF in human pancreatic cancer cells. J Surg Res 167(2), 173–181, 2011.
   PubMed Web of Science ®Google Scholar
• Nelson JA and Falk RE: The efficacy of phloridzin and phloretin on tumor cell growth. Anticancer Res 13, 2287–2292, 1993.
   PubMed Web of Science ®Google Scholar
• Kobori M, Shinmoto H, Tsushida T, and Shinohara K: Phloretin-induced apoptosis in B16 melanoma 4A5 cells by inhibition of glucose transmembrane transport. Cancer Lett 119, 207–212, 1997.
   PubMed Web of Science ®Google Scholar
• Cao X, Fang XL, Gibbs S, Huang Y, Dai Z, et al.: Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother Pharmacol 59, 495–505, 2007.
   PubMed Web of Science ®Google Scholar
• Pathania D, Millard M, and Neamati N: Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Adv Drug Deliv Rev 61, 1250–1275, 2009.
   PubMed Web of Science ®Google Scholar
• Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A, and Saavedra E: Energy metabolism in tumor cells. FEBS J 274, 1393–1418, 2007.
   PubMed Web of Science ®Google Scholar
• Mathupala SP, Ko YH, and Pedersen PL: Hexokinase II cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25, 4777–4786, 2006.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Butler EB, and Tan M: Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 4, e532, 2013.
   PubMed Web of Science ®Google Scholar
• Dando I, Cordani M, and Donadelli M: Mutant p53 and mTOR/PKM2 regulation in cancer cells. IUBMB Life 68(9), 722–726, 2016.
   PubMed Web of Science ®Google Scholar
• Shen Y, Chen M, Huang S, and Zou X: Pantoprazole inhibits human gastric adenocarcinoma SGC–7901 cells by downregulating the expression of pyruvate kinase M2. Oncol Lett 11(1), 717–722, 2016.
   PubMed Web of Science ®Google Scholar
• Chahar MK, Sharma N, Dobhal MP, and Joshi YC: Flavonoids: a versatile source of anticancer drugs. Pharmacogn Rev 5, 1–12, 2011.
   PubMedGoogle Scholar
• Ravishankar D, Rajora AK, Greco F, and Osborn HMI: Flavonoids as prospective compounds for anti-cancer therapy. Int J Biochem Cell Biol 45, 2821–2831, 2013.
   PubMed Web of Science ®Google Scholar
• Adem S, Aslan A, Ahmed I, Krohn K, Guler C, et al.: Inhibitory and activating effects of some flavonoid derivatives on human pyruvate kinase isoenzyme M2. Arch Pharm (Weinheim) 349(2), 132–136, 2016.
   PubMed Web of Science ®Google Scholar
• Sun F, Zheng XY, Ye J, Wu TT, Wang Jl, et al.: Potential anticancer activity of myricetin in human T24 bladder cancer cells both in vitro and in vivo. Nutr Cancer 64(4), 599–606, 2012.
   PubMed Web of Science ®Google Scholar
• Adhami VM, Syed DN, Khan N, and Mukhtar H: Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management. Biochem Pharmacol 84, 1277–1281, 2012.
   PubMed Web of Science ®Google Scholar
• Aslan E, Guler C, and Adem S: In vitro effects of some flavonoids and phenolic acids on human pyruvate kinase isoenzyme M2. J Enzyme Inhib Med Chem 31(2), 314–317, 2016.
   PubMed Web of Science ®Google Scholar
• Aslan E and Adem S: In vitro effects of some flavones on human pyruvate kinase isoenzyme M2. J Biochem Mol Toxicol 29(3), 109–113, 2015.
   PubMed Web of Science ®Google Scholar
• Sullivan EJ, Kurtoglu M, Brenneman R, Liu H, and Lampidis TJ: Targeting cisplatin-resistant human tumor cells with metabolic inhibitors. Cancer Chemother Pharmacol 73, 417–427, 2014.
   PubMed Web of Science ®Google Scholar
• Lisanti MP, Martinez-Outschoorn UE, and Sotgia F: Oncogenes induce the cancer-associated fibroblast phenotype: metabolic symbiosis and ‘‘fibroblast addiction’’ are new therapeutic targets for drug discovery. Cell Cycle 12, 2723–2732, 2013.
   PubMed Web of Science ®Google Scholar
• Sottile ML, Losinno AD, Fanelli MA, Cuello-Carrión FD, Montt-Guevara MM, et al.: Hyperthermia effects on Hsp27 and Hsp72 associations with mismatch repair (MMR) proteins and cisplatin toxicity in MMR-deficient/proficient colon cancer cell lines. Int J Hyperthermia 31(5), 464–475, 2015.
   PubMed Web of Science ®Google Scholar
• Gerweck LE and Richards B: Influence of pH on the thermal sensitivity of cultured human glioblastoma cells. Cancer Res 41, 845–849, 1981.
   PubMed Web of Science ®Google Scholar
• Jones EL, Oleson JR, Prosnitz LR, Samulski TV, Vujaskovic Z, et al.: Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol 23, 3079–3085, 2005.
   PubMed Web of Science ®Google Scholar
• Jahde E and Radjewsky MF: Tumor selected modification of cellular microenvironment in vivo: Effect of glucose infusion on the pH in normal and malignant rat tissues. Cancer Res 42, 1505–1512, 1982.
   PubMed Web of Science ®Google Scholar
• Hiraoka M and Hahn GM: Changes in pH and blood flow induced by glucose, and their effects on hyperthermia with or without BCNU in RIF-I tumors. Int J Hypertherm 6, 97–103, 1990.
   PubMed Web of Science ®Google Scholar
• Gerweck LE: Modification of cell lethality at elevated temperatures. The pH effect. Radiat Res 70, 224–235, 1977.
   PubMed Web of Science ®Google Scholar
• Dixon JA and Calderwood SK: Effects of hyperglycemia and hyperthermia on the pH, glycolysis and respiration of the Yoshida sarcoma in vivo. JNCI 63, 1371–1381, 1979.
   PubMedGoogle Scholar
• Lyons JC, Kim GE, and Song CW: Modification of intracellular pH and thermosensitivity. Radiat Res 129, 79–87, 1992.
   PubMed Web of Science ®Google Scholar
• Wahl ML, Bobyock SB, Leeper DB, and Owen CS: Effects of 428C hyperthermia on intracellular pH in ovarian carcinoma cells during acute or chronic exposure to low extracellular pH. Int J Radiat Oncol Biol Phys 38, 205–212, 1997.
   Web of Science ®Google Scholar
• Dewhirst MW, Vujaskovic Z, Jones E, and Thrall D: Re-setting the biologic rationale for thermal therapy. Int J Hyperthermia 21, 779–790, 2005.
   PubMed Web of Science ®Google Scholar
• Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, et al.: The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 43, 33–56, 2002.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim SH and Alfieri AA: Interaction of rhodamine 123 and hyperthermia in HeLa cells in culture. Int J Hyperthermia 1, 247–253, 1985.
   PubMedGoogle Scholar
• Kim SH, Kim JH and Hahn EW: Selective potentiation of hyperthermic killing of hypoxic cells by 5-thio-o-glucose. Cancer Res 38, 2935–2938, 1978.
   PubMed Web of Science ®Google Scholar
• Koishi M, Hosokawa N, Sato M, Nakai A, Hirayoshi K, et al.: Quercetin, an inhibitor of heat shock protein synthesis, inhibits the acquisition of thermo-tolerance in a human colon carcinoma cell line. Jpn J Cancer Res 83, 1216–1222, 1992.
   PubMedGoogle Scholar
• Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, et al.: Phase I clinical trial of the flavonoid quercetin: Pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 2, 659–668, 1996.
   PubMed Web of Science ®Google Scholar
• Shen F, Herenyiova M, and Weber G: Synergestic down-regulation of signal transduction and cytotoxicity by tiazofurin and quercetin in human ovarian carcinoma cells. Life Sci 65, 1869–1876, 1999.
   Web of Science ®Google Scholar
• Wei Y, Zhao X, Kariya Y, Fukagta H, Teshigawara K, et al.: Induction of apoptosis by quercetin: involvement of heat shock protein. Cancer Res 54, 4952–7495, 1994.
   PubMed Web of Science ®Google Scholar
• Orsolic N, Sver L, Terzić S, and Basić I: Peroral application of water-soluble derivative of propolis (WSDP) and its related polyphenoliccompounds and their influence on immunological and antitumour activity. Vet Res Commun 29(7), 575–593, 2005.
   PubMed Web of Science ®Google Scholar
• Oršolić N, Benković V, Li s ičić D, Erhard J, and Horvat-Knežević A: Protective effects of propolis and related polyphenolic/flavonoid compounds against toxicity induced by irinotecan. Med Oncol 27, 1346–1358, 2010.
   PubMed Web of Science ®Google Scholar
• Yousef MI, Saad AA, and El-Shennawy LK: Protective effect of grape seed proanthocyanidin extract against oxidative stress induced by cisplatin in rats. Food Chem Toxicol 47, 1176–1183, 2009.
   PubMed Web of Science ®Google Scholar
• Sharma H, Sen S, and Singh N: Molecular pathways in the chemosensitization of cisplatin by quercetin in human head and neck cancer. Cancer Biol Ther 4, 949–955, 2005.
   PubMed Web of Science ®Google Scholar
• Ferry DR, Smith A, Malkhandi J, Fyfe DW, de Takats PG, et al.: Phase I clinical trial of the avonoid quercetin: pharmacoki-netics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 2, 659–668, 1996.
   PubMed Web of Science ®Google Scholar
• Flessner MF: The transport barrier in intraperitoneal therapy. Am J Physiol Renal Physiol 288, F433–F442, 2005.
   PubMed Web of Science ®Google Scholar
• Beebe TJ, Johnson CD, Stoner SM, Anderson KJ, and Limburg PJ: Assessing attitudes toward laxative preparation in colorectal cancer screening and effects on future testing: potential receptivity to computed tomographic colonography. Mayo Clin Proc 82, 666–671, 2007.
   PubMed Web of Science ®Google Scholar
• Calderwood SK and Asea A: Targeting HSP70-induced thermo-tolerance for design of thermal sensitizers. Int J Hyperthermia 18, 597–608, 2002.
   PubMed Web of Science ®Google Scholar
• Yuan ZQ, Peng YZ, Li XL, Huang YS, and Yang ZC: Induction of heat shock protein 70 by sodium arsenite attenuates burn-induced intestinal injury in severe burned rats. Burns 34, 247–253, 2008.
   PubMed Web of Science ®Google Scholar
• Secomb TW, Hsu R, Ong ET, Gross JF, and Dewhirst MW: Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncol 34, 313–316, 1995.
   PubMed Web of Science ®Google Scholar
• Kallinowski F, Frills RR, Van Roy RF, and Vaupel P: Oxygenation of tumors derived from ras-transformed cells. Adv Exp Med XII 907–916, 1990.
   Google Scholar
• Pavlovic M, Wroblewski K, Manevich Y, Kim S, and Biaglow JE: The importance of choice of anesthetics in studying radiation effects in the 9L rat glioma. Br J Cancer 73, S01–S04, 1996.
   PubMed Web of Science ®Google Scholar
• Varnes ME, Biaglow JE, and Tuttle SW: Role of cellular non-protein thiols in oxygen consumption and peroxide reduction. Adv Exp Med Biol 200, 565–571, 1986.
   PubMedGoogle Scholar
• Kuin A, Smets L, Volk T, Paans A, Adams G, et al.: Modulation of intratumoral pH by the mitochondrial inhibitor m-iodobenzylguanidine and moderate hyperglycemia. Cancer Res 54, 3785–3792, 1994.
   PubMed Web of Science ®Google Scholar
• Sharma H, Sen S, and Singh N: Molecular pathways in the chemosensitization of cisplatin by quercetin in human head and neck cancer. Cancer Biol Ther 4, 949–955, 2005.
   PubMed Web of Science ®Google Scholar
• Benkovic V, Horvat Knezevic A, DikicD LisicicD, Orsolic N, et al.: Radioprotective effects of propolis and quercetin gamma-irradiated mice evaluated by the alkaline comet assay. Phytomedicine 15, 851–858, 1994.
   Web of Science ®Google Scholar
• Oršolić N, Benković V, Horvat-Knežević A, Kopjar N, Kosalec I, et al.: Assessment by survival analysis of the radioprotective properties of propolis and its polyphenolic compounds. Biol Pharm Bull 30, 946–951, 2007.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim SH, Alfieri AA, and Young CW: Quercetin, an inhibitor of lactate transport and a hyperthermic sensitizer of HeLa cells. Cancer Res 44, 102–106, 1984.
   PubMed Web of Science ®Google Scholar
• Oršolić N and Car N: Quercetin and hyperthermia modulate cisplatin-induced DNA damage in tumor and normal tissues in vivo. Tumour Biol 35(7), 6445–6454, 2014.
   PubMed Web of Science ®Google Scholar
• Cimini A, d'Angelo M, Benedetti E, D'Angelo B, Laurenti G, et al.: Flavopiridol: An old drug with new perspectives? Implication for development of new drugs. J Cell Physiol 232(2), 312–322, 2017.
   PubMed Web of Science ®Google Scholar
• Wang G, Wang J, Zhao H, Wang J, Tony To SS: The role of Myc and let–7a in glioblastoma, glucose metabolism and response to therapy. Arch Biochem Biophys 580, 84–92, 2015.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Lu N, Qiao C, Ni T, Li Z, et al.: FV–429 induces apoptosis and inhibits glycolysis by inhibiting Akt-mediated phosphorylation of hexokinase II in MDA-MB–231 cells. Mol Carcinog 55(9), 1317–1328, 2016.
   PubMed Web of Science ®Google Scholar
• Wenzel U: Flavonoids as drugs at the small intestinal level. Curr Opin Pharmacol 13(6), 864–868, 2013.
   PubMed Web of Science ®Google Scholar
• Kottra G and Daniel H: Flavonoid glycosides are not transported by the human Na+/glucose transporter when expressed in Xenopus laevis oocytes, but effectively inhibit electrogenic glucose uptake. J Pharmacol Exp Ther 322, 829–835, 2007.
   PubMed Web of Science ®Google Scholar
• Kellett GL, Brot-Laroche E, Mace OJ, and Leturque A: Sugar absorption in the intestine: the role of GLUT2. Annu Rev Nutr 28, 35–54, 2008.
   PubMed Web of Science ®Google Scholar
• Ait-Omar A, Monteiro-Sepulveda M, Poitou C, Le Gall M, Cotillard A, et al.: GLUT2 accumulation in enterocyte apical and intracellular membranes: a study in morbidly obese human subjects and ob/ob and high fat-fed mice. Diabetes 60, 2598–2607, 2011.
   PubMed Web of Science ®Google Scholar
• Kwon O, Eck P, Chen S, Corpe CP, Lee JH, et al.: Inhibition of the intestinal glucose transporter GLUT2 by flavonoids. FASEB J 21, 366–377, 2007.
   PubMed Web of Science ®Google Scholar
• Suksomboon N, Poolsup N, Boonkaew S, and Suthisisang CC: Meta- analysis of the effect of herbal supplement on glycemic control in type 2 diabetes. J Ethnopharmacol 137, 1328–1333, 2011.
   PubMed Web of Science ®Google Scholar
• Goto T, Horita M, Nagai H, Nagatomo A, Nishida N, et al.: Tiliroside, a glycosidic flavonoid, inhibits carbohydrate digestion and glucose absorption in the gastrointestinal tract. Mol Nutr Food Res 56, 435–445, 2012.
   PubMed Web of Science ®Google Scholar
• Li JM, Che CT, Lau CB, Leung PS, and Cheng CH: Inhibition of intestinal and renal Na+– glucose cotransporter by naringenin. Int J Biochem Cell Biol 38, 985–995, 2006.
   PubMed Web of Science ®Google Scholar